A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia type 2
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs NT 501 (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- Sponsors Neurotech USA
- 12 Feb 2019 According to a Neurotech Pharmaceuticals (Neurotech USA) media release, two parallel studies (NCT03319849 and NCT03316300) are sponsored by Neurotech in collaboration with the Lowy Medical Research Institute (LMRI).
- 12 Nov 2018 Status changed from planning to recruiting.
- 27 Jun 2017 New trial record